Beta Bionics (NASDAQ:BBNX) Shares Gap Up – Time to Buy?

Beta Bionics, Inc. (NASDAQ:BBNX) gapped up prior to trading on Monday . The stock had previously closed at $13.08, but opened at $13.69. Beta Bionics shares last traded at $13.25, with a volume of 272,867 shares changing hands.

Analysts Set New Price Targets

Several equities analysts have issued reports on BBNX shares. Piper Sandler restated an “overweight” rating and issued a $32.00 price objective (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. TD Cowen started coverage on Beta Bionics in a report on Monday, January 26th. They issued a “hold” rating and a $17.00 target price for the company. The Goldman Sachs Group restated a “buy” rating and set a $25.00 price target on shares of Beta Bionics in a research note on Thursday, January 15th. Stifel Nicolaus reduced their price objective on Beta Bionics from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Finally, Lake Street Capital increased their price objective on Beta Bionics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $26.42.

Beta Bionics Trading Up 6.0%

The company has a market capitalization of $610.63 million and a PE ratio of -3.17. The firm has a 50 day simple moving average of $24.23 and a two-hundred day simple moving average of $22.66.

Insider Buying and Selling at Beta Bionics

In other Beta Bionics news, insider Mike Mensinger sold 7,800 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.61, for a total transaction of $230,958.00. Following the completion of the transaction, the insider owned 82,952 shares in the company, valued at approximately $2,456,208.72. This represents a 8.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the sale, the chief financial officer owned 42,614 shares of the company’s stock, valued at $1,258,391.42. This trade represents a 31.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 32,490 shares of company stock worth $960,835 over the last three months.

Hedge Funds Weigh In On Beta Bionics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GPS Wealth Strategies Group LLC raised its stake in shares of Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after buying an additional 450 shares in the last quarter. Strs Ohio acquired a new position in Beta Bionics during the first quarter worth $29,000. EverSource Wealth Advisors LLC raised its position in Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after acquiring an additional 1,594 shares in the last quarter. CWM LLC acquired a new stake in Beta Bionics in the second quarter valued at $58,000. Finally, Legal & General Group Plc lifted its holdings in Beta Bionics by 197.4% in the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after acquiring an additional 2,639 shares during the period.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.